<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39333538</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Correlating COVID-19 severity with biomarker profiles and patient prognosis.</ArticleTitle><Pagination><StartPage>22353</StartPage><MedlinePgn>22353</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22353</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-71951-w</ELocationID><Abstract><AbstractText>COVID-19's long-lasting and complex impacts have become a global concern, with diverse clinical outcomes. This study evaluated 226 participants to understand the clinical spectrum of COVID-19/Long COVID (LC), exploring how disease severity correlates with sociodemographic factors and biomarkers. Determinants related to COVID-19 severity included age (P&#x2009;&lt;&#x2009;0.001), lower education (P&#x2009;&lt;&#x2009;0.001), ethnicity (P&#x2009;=&#x2009;0.003), overweight (P&#x2009;&lt;&#x2009;0.001), MTHFR gene rs1801133 (P&#x2009;=&#x2009;0.035), cardiovascular diseases (P&#x2009;=&#x2009;0.002), diabetes mellitus (DM) (P&#x2009;=&#x2009;0.006), Factor VIII (FVIII) (P&#x2009;=&#x2009;0.046), von Willebrand factor (VWF) (P&#x2009;=&#x2009;0.002), and dimer D (DD) (P&#x2009;&lt;&#x2009;0.001). Six months later, in a portion of the monitored participants, a significant reduction in FVIII (P&#x2009;&lt;&#x2009;0.001), VWF (P&#x2009;=&#x2009;0.002), and DD (P&#x2009;&lt;&#x2009;0.001) levels was observed, with only DD returning to normal values. Different systemic sequelae were identified, with higher incidences of joint pain and myalgia in participants with a clinical history of DM, chronic lung disease (CLD) and sustained high interleukin 6 values in the convalescent phase. CLD, COVID-19 severity and high DD levels increased the risk of developing dyspnea and palpitations. Women were more likely to develop lower limb phlebitis long-term, while sustained elevated FVIII in the convalescent phase was associated with an increased risk of swelling. Regular physical activity had a protective effect against swelling. This study highlights factors contributing to COVID-19 severity/LC, emphasizing endothelial cell activation as a potential mechanism.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Danielle</LastName><ForeName>R C S</ForeName><Initials>RCS</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Haemostasis Laboratory, Hemotherapy and Hematology Center of Esp&#xed;rito Santo - HEMOES, Vit&#xf3;ria, 29040-090, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>D&#xe9;bora</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alessandra</LastName><ForeName>N L P</ForeName><Initials>NLP</Initials><AffiliationInfo><Affiliation>Haemostasis Laboratory, Hemotherapy and Hematology Center of Esp&#xed;rito Santo - HEMOES, Vit&#xf3;ria, 29040-090, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexia</LastName><ForeName>S S Z</ForeName><Initials>SSZ</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe9;bora</LastName><ForeName>M C R</ForeName><Initials>MCR</Initials><AffiliationInfo><Affiliation>Haemostasis Laboratory, Hemotherapy and Hematology Center of Esp&#xed;rito Santo - HEMOES, Vit&#xf3;ria, 29040-090, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elizabel</LastName><ForeName>N V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Haemostasis Laboratory, Hemotherapy and Hematology Center of Esp&#xed;rito Santo - HEMOES, Vit&#xf3;ria, 29040-090, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felipe</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giulia</LastName><ForeName>M G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrique</LastName><ForeName>P R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karen</LastName><ForeName>R M B</ForeName><Initials>RMB</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Layane</LastName><ForeName>S B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leandro</LastName><ForeName>A B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livia</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raquel</LastName><ForeName>S R T</ForeName><Initials>SRT</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorena</LastName><ForeName>S C A</ForeName><Initials>SCA</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyvia</LastName><ForeName>N R A</ForeName><Initials>NRA</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariana</LastName><ForeName>T R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheus</LastName><ForeName>C C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vin&#xed;cius</LastName><ForeName>D P V</ForeName><Initials>DPV</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasmin</LastName><ForeName>M G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>I&#xfa;ri</LastName><ForeName>D L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Federal University of Esp&#xed;rito Santo, Vit&#xf3;ria, 29075-910, Brazil. iurilouro@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>485/2021 - 44770.706.17823.29042021</GrantID><Agency>FUNDA&#xc7;&#xc3;O DE AMPARO A PESQUISA DO ESP&#xcd;RITO SANTO</Agency><Country/></Grant><Grant><GrantID>485/2021 - 44770.706.17823.29042021</GrantID><Agency>FUNDA&#xc7;&#xc3;O DE AMPARO A PESQUISA DO ESP&#xcd;RITO SANTO</Agency><Country/></Grant><Grant><GrantID>408777/2022-2</GrantID><Agency>Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico</Agency><Country/></Grant><Grant><GrantID>408777/2022-2</GrantID><Agency>Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-27-8</RegistryNumber><NameOfSubstance UI="D005169">Factor VIII</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="Y">von Willebrand Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005169" MajorTopicYN="N">Factor VIII</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Severity</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333538</ArticleId><ArticleId IdType="pmc">PMC11436624</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-71951-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-71951-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). Coronavirus disease (COVID-19): Post COVID-19 condition (2023).</Citation></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol.21(3), 133&#x2013;146. 10.1038/s41579-022-00846-2 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler, D. M. The Costs of Long COVID. JAMA Health Forum3(5), e221809. 10.1001/jamahealthforum.2022.1809 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba, T., Connors, J. M. &amp; Levy, J. H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm. Res.69(12), 1181&#x2013;1189. 10.1007/s00011-020-01401-6 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7486586</ArticleId><ArticleId IdType="pubmed">32918567</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing, H. et al. Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Front. Immunol.13, 992384. 10.3389/fimmu.2022.992384 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9709252</ArticleId><ArticleId IdType="pubmed">36466841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler, C. et al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science.383(6680), 7942. 10.1126/science.adg7942 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed, J. &amp; Laurence, J. Long COVID endotheliopathy: Hypothesized mechanisms and potential therapeutic approaches. J. Clin. Invest.132(15), e161167. 10.1172/JCI161167 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol Research Foundation. EQ-5D-5L User Guide. Dispon&#xed;vel em: https://euroqol.org/publications/user-guides (2018).</Citation></Reference><Reference><Citation>Ledford, H. Long COVID is a double curse in low-income nations&#x2014;here&#x2019;s why. Nature.625(7993), 20&#x2013;22. 10.1038/d41586-023-04088-x (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38172361</ArticleId></ArticleIdList></Reference><Reference><Citation>Zsichla, L. &amp; M&#xfc;ller, V. Risk factors of severe COVID-19: A review of host, viral and environmental factors. Viruses.15(1), 175. 10.3390/v15010175 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9863423</ArticleId><ArticleId IdType="pubmed">36680215</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung, T. J. et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. EClinicalMedicine.53, 1. 10.1016/j.eclinm.2022.101651 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482331</ArticleId><ArticleId IdType="pubmed">36133318</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, B. et al. Prevalence, risk factors and treatments for post-COVID-19 breathlessness: A systematic review and meta-analysis. Eur. Respir. Rev.31(166), 1. 10.1183/16000617.0071-2022 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9724798</ArticleId><ArticleId IdType="pubmed">36323418</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, E. M. COVID-19 vaccines for low-and middle-income countries. Trans. R Soc. Trop. Med. Hug.115(5), 447&#x2013;456. 10.1093/trstmh/trab045 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989148</ArticleId><ArticleId IdType="pubmed">33733663</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw, E., Yashadhana, A. &amp; Hitch, D. Long COVID: Sustained and multiplied disadvantage. Med. J. Aust.216(5), 222&#x2013;224. 10.5694/mja2.51435 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115005</ArticleId><ArticleId IdType="pubmed">35249215</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos Silva, L., da Concei&#xe7;&#xe3;o Barbosa, R. B., Lima, J. P. et al. Racial inequalities in the health establishment access to the treatment of COVID-19 in Brazil in 2020. J. Racial Ethn. Health Disparities. 1&#x2013;12. 10.1007/s40615-023-01866-1 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38189902</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew, S. C. &amp; Gupta, E. D. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur. J. Med. Genet.58(1), 1&#x2013;10. 10.1016/j.ejmg.2014.10.004 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25449138</ArticleId></ArticleIdList></Reference><Reference><Citation>Timizheva, K. B. et al. Association of the DNA methyltransferase and folate cycle enzymes&#x2019; gene polymorphisms with coronary restenosis. Life.12(2), 245. 10.3390/life12020245 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8879581</ArticleId><ArticleId IdType="pubmed">35207533</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivkar, R. R. et al. Association of MTHFR C677T (rs1801133) and A1298C (rs1801131) polymorphisms with serum homocysteine, folate and vitamin B12 in patients with young coronary artery disease. Ind. J. Clin. Biochem.37, 224&#x2013;231. 10.1007/s12291-021-00982-1 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993972</ArticleId><ArticleId IdType="pubmed">35463099</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg, A., et al. Cardiovascular and cerebrovascular complications with COVID-19. Cardiol. Rev.29(3), 143&#x2013;149. 10.1097/CRD.0000000000000385 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8021013</ArticleId><ArticleId IdType="pubmed">33758123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai, W. K. C. &amp; Kan, M. Y. Homocysteine-induced endothelial dysfunction. Ann. Nutr. Metab.67(1), 1&#x2013;12. 10.1159/000437098 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26201664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, S. et al. Homocysteine-induced oxidative stress through TLR4/NF-&#x3ba;B/DNMT1-mediated LOX-1 DNA methylation in endothelial cells. Mol. Med. Rep.16, 9181&#x2013;9188. 10.3892/mmr.2017.7753 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29039510</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur, B. et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci. Rep.11, 8562. 10.1038/s41598-021-88130-w (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058064</ArticleId><ArticleId IdType="pubmed">33879826</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, L. Z. et al. The most important biomarker associated with coagulation and inflammation among COVID-19 patients. Mol. Cell Biochem.476, 2877&#x2013;2885. 10.1007/s11010-021-04122-4 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978444</ArticleId><ArticleId IdType="pubmed">33742367</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyvandi, F. et al. Hemostatic alterations in COVID-19. Haematologica.106(5), 1472. 10.3324/haematol.2020.262634 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094101</ArticleId><ArticleId IdType="pubmed">32855280</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami, M., Mansouritorghabeh, H. &amp; Parsa-Kondelaji, M. High levels of Von Willebrand factor markers in COVID-19: A systematic review and meta-analysis. Clin. Exp. Med.22, 347&#x2013;357. 10.1007/s10238-021-00769-x (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8571968</ArticleId><ArticleId IdType="pubmed">34741678</ArticleId></ArticleIdList></Reference><Reference><Citation>Valencia, I., et al. Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: A link with diabetes mellitus. Cardiovasc. Diabetol.23(1), 75. 10.1186/s12933-023-02097-8 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10880237</ArticleId><ArticleId IdType="pubmed">38378550</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf3;jcik, K. et al. Decreased protein C activity, lower ADAMTS13 antigen and free protein S levels accompanied by unchanged thrombin generation potential in hospitalized COVID-19 patients. Thromb. Res.223, 80&#x2013;86. 10.1016/j.thromres.2023.01.016 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9872442</ArticleId><ArticleId IdType="pubmed">36709678</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardani, R. et al. Association between serum inflammatory parameters and the disease severity in COVID-19 patients. J. Clin. Lab. Anal.36(1), e24162. 10.1002/jcla.24162 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761446</ArticleId><ArticleId IdType="pubmed">34874079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Z., Du, Z. &amp; Zhu, F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res. Clin. Tract.164, 108214. 10.1016/j.diabres.2020.108214 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233217</ArticleId><ArticleId IdType="pubmed">32416121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellone, S., Siegel, E. R., Scheim, D. E. &amp; Santin, A. D. Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID. Gynecol. Oncol. Rep.51, 101324. 10.1016/j.gore.2024.10132 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10809113</ArticleId><ArticleId IdType="pubmed">38273933</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt, F. A. et al. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv.5(3), 756&#x2013;759. 10.1182/bloodadvances.2020003968 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857699</ArticleId><ArticleId IdType="pubmed">33560386</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty, H., et al. Irish COVID-19 vasculopathy study (iCVS) investigators. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J. Thromb. Haemost.20(10), 2429&#x2013;2438. 10.1111/jth.15830 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349977</ArticleId><ArticleId IdType="pubmed">35875995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger, A. et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc. Diabetol.21, 190. 10.1186/s12933-022-01623-4 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, J. H. et al. Musculoskeletal complications in patients with diabetes mellitus. Kor. J. Intern. Med.37(6), 1099&#x2013;1110. 10.3904/kjim.2022.168 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9666255</ArticleId><ArticleId IdType="pubmed">36300322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal, J. et al. High prevalence of post COVID-19 fatigue in patients with type 2 diabetes: A case-control study. Diabetes Metab. Syndr.15(6), 102302. 10.1016/j.dsx.2021.102302 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8462068</ArticleId><ArticleId IdType="pubmed">34626924</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman, E. L. et al. COVID-19 and diabetes: A collision and collusion of two diseases. Diabetes.69(12), 2549&#x2013;2565. 10.2337/dbi20-0032 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7679769</ArticleId><ArticleId IdType="pubmed">32938731</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzeni, F., Nucera, V., Masala, I. F., Sarzi-Puttini, P. &amp; Bonitta, G. Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of IL-6 inhibitor sarilumab. Pharmacol. Res.149, 104402. 10.1016/j.phrs.2019.104402 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31536783</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue, J. K. et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw. Open.4(2), e210830&#x2013;e210830. 10.1001/jamanetworkopen.2021.0830 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchetto, A. et al. Dyspnea in post-acute COVID-19: A multi-parametric cardiopulmonary evaluation. J. Clin. Med.12(14), 4658. 10.3390/jcm12144658 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10380208</ArticleId><ArticleId IdType="pubmed">37510773</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaramuzzo, G. et al. Long-term dyspnea, regional ventilation distribution and peripheral lung function in COVID-19 survivors: A 1 year follow up study. BMC Pulm. Med.22, 408. 10.1186/s12890-022-02214-5 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9643983</ArticleId><ArticleId IdType="pubmed">36352423</ArticleId></ArticleIdList></Reference><Reference><Citation>Weerahandi, H. et al. Post-discharge health status and symptoms in patients with severe COVID-19. J. Gen. Intern. Med.36(3), 738&#x2013;745. 10.1007/s11606-020-06338-4 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808113</ArticleId><ArticleId IdType="pubmed">33443703</ArticleId></ArticleIdList></Reference><Reference><Citation>Konkol, S. B. et al. Differences in lung function between major race/ethnicity groups following hospitalization with COVID-19. Respir. Med.201, 106939. 10.1016/j.rmed.2022.106939 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9357276</ArticleId><ArticleId IdType="pubmed">36029696</ArticleId></ArticleIdList></Reference><Reference><Citation>Khullar, D. et al. Racial/ethnic disparities in post-acute sequelae of SARS-CoV-2 infection in New York: An EHR-based cohort study from the recover program. J. Gen. Intern. Med.38(5), 1127&#x2013;1136. 10.1007/s11606-022-07997-1 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933823</ArticleId><ArticleId IdType="pubmed">36795327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaivani, M. K. &amp; Dinakar, S. Association between D-dimer levels and post-acute sequelae of SARS-CoV-2 in patients from a tertiary care center. Biomark. Med.16(11), 833&#x2013;838. 10.2217/bmm-2022-0050 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35787147</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh, S. K., Al Mamun, A. &amp; Majumder, A. Clinical presentation of varicose veins. Indian J. Surg.85(Suppl 1), 7&#x2013;14. 10.1007/s12262-021-02946-4 (2023).</Citation></Reference><Reference><Citation>Turner, S. et al. Long COVID: Pathophysiological factors and abnormalities of coagulation. Trends Endocrinol. Metab.34(6), 321&#x2013;344. 10.1016/j.tem.2023.03.002 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113134</ArticleId><ArticleId IdType="pubmed">37080828</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik, P. et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)&#x2014;A systematic review and meta-analysis. J. Med. Virol.94(1), 253&#x2013;262. 10.1002/jmv.27309 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinar-Herranz, K. et al. Memory, emotion, and quality of life in patients with long COVID-19. Brain Sci.13(12), 1670. 10.3390/brainsci13121670 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10742100</ArticleId><ArticleId IdType="pubmed">38137118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, Y. et al. Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. Sci. Rep.13, 11207. 10.1038/s41598-023-36995-4 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10336045</ArticleId><ArticleId IdType="pubmed">37433819</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;lez-Santamar&#xed;a, R. et al. Functionality, physical activity, fatigue and quality of life in patients with acute COVID-19 and Long COVID infection. Sci. Rep.13, 19907. 10.1038/s41598-023-47218-1 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10645778</ArticleId><ArticleId IdType="pubmed">37963962</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjenberg, Z. et al. Risk of long COVID main symptoms after SARS-CoV-2 infection: A systematic review and meta-analysis. Sci. Rep.13, 15332. 10.1038/s41598-023-42321-9 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504382</ArticleId><ArticleId IdType="pubmed">37714919</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira, F.E.G., Griep, R.H., Chor, D. et al. Racial inequalities in multimorbidity: baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). BMC Public Health22, 1319. 10.1186/s12889-022-13715-7. (2022)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9270815</ArticleId><ArticleId IdType="pubmed">35810284</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Clinical management of COVID-19: living guideline (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">35917394</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/ (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume, J. D., Su, L., Olveda, R. M. &amp; McGarvey, S. T. Statistical evidence for GLM regression parameters: A robust likelihood approach. Stat. Med.26(15), 2919&#x2013;2936. 10.1002/sim.2759 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17211856</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>